LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Search

Penumbra Inc

Gesloten

SectorGezondheidszorg

279.92 -1.18

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

277.08

Max

284.4

Belangrijke statistieken

By Trading Economics

Inkomsten

581K

46M

Verkoop

15M

355M

K/W

Sectorgemiddelde

66.629

106.172

Winstmarge

12.927

Werknemers

4,500

EBITDA

4M

55M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+8.36% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.1B

11B

Vorige openingsprijs

281.1

Vorige sluitingsprijs

279.92

Nieuwssentiment

By Acuity

50%

50%

182 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Penumbra Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 nov 2025, 23:07 UTC

Marktinformatie

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 nov 2025, 22:22 UTC

Marktinformatie

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 nov 2025, 22:08 UTC

Marktinformatie

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 nov 2025, 21:57 UTC

Winsten

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 nov 2025, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

20 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

20 nov 2025, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

20 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

20 nov 2025, 21:31 UTC

Winsten

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 nov 2025, 21:23 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 nov 2025, 21:07 UTC

Winsten

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:06 UTC

Winsten

Webull 3Q Rev $156.9M >BULL

20 nov 2025, 21:06 UTC

Winsten

Webull 3Q EPS 7c >BULL

20 nov 2025, 21:05 UTC

Winsten

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 nov 2025, 21:04 UTC

Winsten

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 nov 2025, 21:04 UTC

Winsten

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 nov 2025, 21:04 UTC

Winsten

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:00 UTC

Winsten

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 nov 2025, 21:00 UTC

Winsten

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 nov 2025, 21:00 UTC

Winsten

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 nov 2025, 21:00 UTC

Winsten

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 nov 2025, 21:00 UTC

Winsten

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit 1Q Consumer Rev $894M

20 nov 2025, 21:00 UTC

Winsten

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit Backs FY26 Guidance

20 nov 2025, 21:00 UTC

Winsten

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 nov 2025, 21:00 UTC

Winsten

Intuit 1Q Global Business Solutions Rev $3B

Peer Vergelijking

Prijswijziging

Penumbra Inc Prognose

Koersdoel

By TipRanks

8.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 306.82 USD  8.36%

Hoogste 355 USD

Laagste 266 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Penumbra Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technische score

By Trading Central

288.28 / 292.9394Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

182 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat